Mostrar el registro sencillo del ítem

Comportamiento del implante subdérmico de etonogestrel en comparación con el método inyectable trimestral de acetato de medroxiprogesterona en el puerperio en una población de pacientes en el Hospital Militar Central – Segunda fase (seguimiento a dos años)

dc.contributor.advisorDíaz Yamal, Ivonne Jeanettespa
dc.contributor.authorEcheverry Pérez, Lesley Estefanía
dc.contributor.authorLerma Ruíz, Yudy Alexandra
dc.contributor.otherQuintero Ruíz, Claudia Ceciliaspa
dc.contributor.otherArenas Rodríguez, Vanessaspa
dc.coverage.spatialMedicinaspa
dc.date.accessioned2020-02-25T19:20:28Z
dc.date.available2020-02-25T19:20:28Z
dc.date.issued2019-11-06
dc.identifier.urihttp://hdl.handle.net/10654/34914
dc.description.abstractLa Organización Mundial de la Salud recomienda el inicio durante el posparto inmediato de anticonceptivos de progestágeno en mujeres lactantes con un alto riesgo de aumento de la morbi-mortalidad. Aunque algunos estudios han evaluado la administración de acetato de medroxiprogesterona de depósito o del implante liberador de etonorgestrel durante el período de puerperio inmediato, sin que se observen efectos deleteros sobre la seguridad materna o neonatal; no han comparado las tasas de continuidad de los mismos y las razones para descontinuarlos. Se realizó un estudio de cohorte prospectivo en el que se siguieron durante 24 meses, 133 mujeres quienes en su puerperio entre 01/Mayo/ 2016 y el 31/Jul/2016 escogieron un método de planificación basado en progestinas. El resultado demostró que la efectividad y continuidad del implante subdérmico es mayor en comparación con el inyectable trimestral, además de que los efectos secundarios mejoran en el transcurso del tiempo. Comprender estas diferencias y otros atributos del método es una herramienta que permite ayudar las mujeres tomar una decisión informada sobre qué anticonceptivo usar.spa
dc.description.tableofcontents1. PORTADA.………………………………………………………………………………….…1 2. TABLA DE CONTENIDOS……………………………………………………………….….2 3. RESUMEN……………………………………………………………………………………..3 4. IDENTIFICACIÓN Y FORMULACIÓN DEL PROBLEMA………………………….….4 5. OBJETIVOS…………………………………………………………………………………...5 5.1 General…………………………………………………………………………………5 5.2 Específicos……………………………………………………………………………..5 6. METODOLOGÍA …………………………………………………………………………….6 6.1. Tipo y diseño general del estudio……………………………………………………..6 6.2. Población……………………………………………………………………………...6 6.3. Selección y tamaño de la Muestra…………………………………………………….6 6.4. Criterios de inclusión y exclusión………………………………………………….....6 6.5. Definición de variables………………………………………………………………..7 6.6. Procedimientos para la recolección de la información, instrumentos a utilizar..……..7 7. PLAN DE ANÁLISIS…………………….……………………………………………………8 7.1. Métodos y modelos de análisis de los datos según el tipo de variables………..….......8 7.2. Programas a utilizar en el análisis de datos…………………..…………………….....8 8. ASPECTOS ÉTICOS.………………………………………………………………………..10 9. RESULTADOS……………………………………………………………………………….12 10. DISCUSIÓN………...……………………………………………………………………….20 11. CONCLUSIÓNES………………………………………………………………………......22 12. BIBLIOGRAFIA……………………………………………………………………………23 13. ANEXOS……………………………………………………………………………………..26 13.1. A. Consentimiento informado………………………………………………………26 13.2. B. Asentimiento informado…………………………………………………………30 13.2. C. Formato de recolección de los datos…………………………………………….32 13.3. D. Variables…………………………..…………………………………………….33 14. GRAFICOS Y TABLAS..…………………………………………………………………..38spa
dc.formatpdfspa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.language.isospaspa
dc.publisherUniversidad Militar Nueva Granadaspa
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.5/co/spa
dc.titleComportamiento del implante subdérmico de etonogestrel en comparación con el método inyectable trimestral de acetato de medroxiprogesterona en el puerperio en una población de pacientes en el Hospital Militar Central – Segunda fase (seguimiento a dos años)spa
dc.typeinfo:eu-repo/semantics/bachelorThesisspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.subject.lembIMPLANTE SUBDERMICOspa
dc.subject.lembPROGESTINAspa
dc.subject.lembACETATO DE MEDROXIPROGESTERONAspa
dc.publisher.departmentFacultad de Medicinaspa
dc.type.localTrabajo de gradospa
dc.description.abstractenglishThe World Health Organization recommends the start during the immediate postpartum period of progestin contraceptives in nursing women with a high risk of increased morbidity and mortality. Although some studies have evaluated the administration of depot medroxyprogesterone acetate or the etonorgestrel-releasing implant during the immediate postpartum period, with no deleterious effects on maternal or neonatal safety; they have not compared their continuity rates and the reasons for discontinuing them. A prospective cohort study was conducted in which 24 women were followed for 24 months, who in their puerperium between 01 / May / 2016 and 31 / Jul / 2016 chose a progestin-based planning method. The result showed that the effectiveness and continuity of the subdermal implant is greater compared to the injectable quarterly, in addition to the fact that the side effects improve over time. Understanding these differences and other attributes of the method is a tool that helps women make an informed decision about what contraceptive to use.eng
dc.title.translatedBehavior of the subdermal implant of etonogestrel compared to the quarterly injectable method of medroxyprogesterone acetate in the puerperium of a patient population at the Hospital Militar Central - Second phase (two-year follow-up)spa
dc.subject.keywordsContraceptionspa
dc.subject.keywordsPuerperiumspa
dc.subject.keywordsProgestinspa
dc.subject.keywordsSubdermic implantspa
dc.subject.keywordsMedroxyprogesterone acetatespa
dc.publisher.programGinecología y obstetriciaspa
dc.creator.degreenameEspecialista en Ginecología y obstetriciaspa
dc.subject.decsGINECOLOGIA
dc.subject.decsANTICONCEPCION
dc.subject.decsPUERPERIO
dc.description.degreelevelEspecializaciónspa
dc.publisher.facultyMedicina y Ciencias de la Salud - Ginecología y obstetriciaspa
dc.type.dcmi-type-vocabularyTextspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadasspa
dc.relation.references1. Sober S, Schreiber C. Postpartum Contraception. Clin Obstet Gynecol. 2014;57:763-776. DOI: 10.1097/GRF.0000000000000055spa
dc.relation.references2. Cwiak C, Gellasch T, Zieman M. Peripartum contraceptive attitudes and practices. Contraception. 2004;70:383–386. DOI: 10.1016/j.contraception.2004.05.010spa
dc.relation.references3. Speroff L, Mishell DR Jr. The postpartum visit: It’s time for a change in order to optimally initiate contraception. Contraception. 2008;78: 90–98. DOI: 10.1016/j.contraception.2008.04.005spa
dc.relation.references4. World Health Organization. Progestogen-only contraceptives during lactation: II. Infant development. World Health Organization, Task Force for Epidemiological Research on Reproductive Health; Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 50:55–68. DOI: https://doi.org/10.1016/0010-7824(94)90080-9spa
dc.relation.references5. P. Gourdy et al. Hormonal contraception in women at risk of vascular and metabolic disorders: Guidelines of the French Society of EndocrinologyContraception hormonale chez la femme à risque vasculaire et métabolique: recommandations de la Société française d’endocrinologie. Annales d'Endocrinologie. 2012; 73: 469-487 DOI: https://doi.org/10.1016/j.ando.2012.09.001spa
dc.relation.references6. Rodriguez MI, Kaunitz AM. An evidence-based approach to postpartum use of depot medroxyprogesterone acetate in breastfeeding women. Contraception. 2009;80:4–6. DOI: 10.1016/j.contraception.2008.12.014spa
dc.relation.references7. S. Wilson et al. Immediate postpartum etonogestrel implant: a contraception option with long-term continuation. Contraception. 2014;90: 259–264. DOI: 10.1016/j.contraception.2014.05.006spa
dc.relation.references8. S.J. Phillips et al. Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception. 2016;94:226–252. DOI: 10.1016/j.contraception.2015.09.010spa
dc.relation.references9. Centers for Disease Control and Prevention (CDC). US Medical Eligibility Criteria for Contraceptive Use. 2010. Disponible en: www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdfspa
dc.relation.references10. Royer PA, Jones KP. Progestins for Contraception: Modern Delivery Systems and Novel Formulations. Clin Obs and Gyn. 2014; 57:644-658. DOI: 10.1097/GRF.0000000000000072spa
dc.relation.references11. Liu A, Margai I, Zhang Set al. Progesteron receptors: a key for neuroprotection in experimental stroke. Endocrinology. 2012;153:374. DOI: 10.1210/en.2012-1138spa
dc.relation.references12. Baron TH, Ramirez B, Richter JE. Gastrointestinal motility disorders during pregnancy. Ann Intern Med. 1993;118:366–375. DOI: 10.7326/0003-4819-118-5-199303010-00008spa
dc.relation.references13. Heit JA, Kobbervig CE, James AH, etal. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143: 697–706. DOI: 10.7326/0003-4819-143-10-200511150-00006spa
dc.relation.references14. Dahlman T, Hellgren M, Blomba ckM. Changes in blood coagulation and fibrinolysis in the normal puerperium. Gynecol Obstet Invest. 1985;20:37–44. DOI: 10.1159/000298969spa
dc.relation.references15. Jackson E, Curtis KM, Gaffield ME. Risk of venous thromboembolism during the postpartum period: a systematic review. Obstet Gynecol. 2011;117:691–703. DOI: 10.1097/AOG.0b013e31820ce2dbspa
dc.relation.references16. Tepper, Naomi K. et al. Progestin-only contraception and thromboembolism: A systematic review. Contraception, Volume 94, Issue 6, 678 – 700. DOI: https://doi.org/10.1016/j.contraception.2016.04.014spa
dc.relation.references17. Blumenthal PD, Gemzell-Danielsson K, MarintchevaPetrova M. Tolerability and clinical safety of Implanon. Eur J Contracept Reprod Health Care 2008;13:29–36. DOI: 10.1080/13625180801960012spa
dc.relation.references18. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 1999;60:1–8. DOI: 10.1016/s0010-7824(99)00053-0spa
dc.relation.references19. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009;91:1646–53. DOI: 10.1016/j.fertnstert.2008.02.140spa
dc.relation.references20. Mishell DR Jr. Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996; 41:381.spa
dc.relation.references21. Ortiz A, Hirol M, Stanczyk FZ, et al. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. JClin Endocrinol Metab 1977; 44:32. DOI: 10.1210/jcem-44-1-32spa
dc.relation.references22. Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397. DOI: 10.1016/j.contraception.2011.01.021spa
dc.relation.references23. Shokoufeh D et al. Side effects and health benefits of Depot Medroxyprogesterone Acetate, A systematic review. Obstetrics & Gynecology 201;133(2):332–341. DOI: 10.1097/AOG.0000000000003089spa
dc.relation.references24. Labbok MH, Hight-Laukaran V, Peterson AE, et al. Multicenter study of the lactational amenorrhea method (LAM): I. Efficacy, duration, and implications for clinical application. Contraception. 1997;55:327–336. DOI: 10.1016/s0010-7824(97)00040-1spa
dc.relation.references25. Kennedy KI, Rivera R, McNeilly AS. Consensus statement on the use of breastfeeding as a family planning method. Contraception. 1989;39:477–496. DOI: 10.1016/0010-7824(89)90103-0spa
dc.relation.references26. Hassoun D. Natural Family Planning methods and Barrier: CNGOF Contraception Guidelines. Gynecologie Obstetrique Fertilite et Senologie 2018 Dec;46(12):873-882. DOI: 10.1016/j.gofs.2018.10.002spa
dc.relation.references27. Yee LM, Kaimal AJ, Nakagawa S, Houston K, Kuppermann M. Predictors of Postpartum Sexual Activity and Function in a Diverse Population of Women J Midwifery Womens Health. 2013 Nov-Dec;58(6):654-61. DOI: 10.1111/jmwh.12068spa
dc.relation.references28. High Impact Practices in Family Planning (HIPs). Family planning high impact practices list. Washington, DC: United States Agency for International Development; 2017. Disonible en: www.fphighimpactpractices.org/high-impact-practices-in-family-planning-list Consultado el 05/10/19.spa
dc.relation.references29. Thiel de Bocanegra H, Chang R, Howell M, Darney P. Interpregnancy intervals: impact of postpartum contraceptive effectiveness and coverage. Am J Obstet Gynecol 2014; 210:311. DOI: 10.1016/j.ajog.2013.12.020spa
dc.relation.references30. Stevens-Simon C, Kelly L, Singer D. Preventing repeat adolescent pregnancies with early adoption of the contraceptive implant. Fam Plann Perspect. 1999; 31: 8893. DOI: https://doi.org/10.1363/3108899spa
dc.relation.references31. Peipert JF, Madden T, Allsworth J, et al. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol. 2012; 120:1291–1297. DOI: 10.1097/AOG.0b013e31828a810aspa
dc.relation.references32. Encuesta Nacional de Demografía y Salud 2015. Disponible en: www.minsalud.gov.co/paginas/ministerio-de-salud-y-profamilia-entregan-resultados-de-la-ENDS-2015.aspx Consultado el 02/04/18spa
dc.relation.references33. Teunissen, A.M., B. Grimm, and F.J. Roumen. Continuation rates of the subdermal contraceptive Implanon® and associated influencing factors. The European Journal of Contraception & Reproductive Health Care, 2014. 19(1): p. 15-21. DOI: 10.3109/13625187.2013.862231spa
dc.relation.references34. Peipert, J.F., et al., Continuation and satisfaction of reversible contraception. Obstetrics and gynecology, 2011. 117(5): p. 1105. DOI: 10.1097/AOG.0b013e31821188adspa
dc.relation.references35. Modesto, W., Bahamondes M.V., Bahamondes L. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives. Human Reproduction, 2014. 29(7): p. 1393-1399. DOI: 10.1093/humrep/deu089spa
dc.subject.proposalAnticoncepciónspa
dc.subject.proposalPuerperiospa
dc.subject.proposalProgestinaspa
dc.subject.proposalImplante subdérmicospa
dc.subject.proposalAcetato de medroxiprogesteronaspa


Archivos en el ítem

Thumbnail
Nombre:
EcheverryPérezLesleyEstefanía- ...
Tamaño:
990.6Kb
Formato:
PDF
Descripción:
Trabajo de grado
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

https://creativecommons.org/licenses/by-nc-nd/2.5/co/
Excepto si se señala otra cosa, la licencia del ítem se describe como https://creativecommons.org/licenses/by-nc-nd/2.5/co/